What changed
Viatris agreed to acquire all outstanding Pacira shares for $36.50 per share in cash, an aggregate equity value of $1.65 billion. Pacira generated approximately $746 million in total revenue and approximately $177 million in adjusted EBITDA for the last twelve months ended June 30, 2026. The deal adds marketed, patent-protected U.S. products EXPAREL and ZILRETTA, is anticipated to close by the end of 2026, and is expected to be immediately accretive to Viatris' financial guidance metrics, funded primarily from excess cash with the remainder from short-term borrowings.
Why it matters
Viatris agreed to acquire all outstanding Pacira shares for $36.50 per share in cash, an aggregate equity value of $1.65 billion. Pacira generated approximately $746 million in total revenue and appro